StoneX Group’s Coherus Oncology CHRS Stock Holding History

StoneX Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,002	Closed	-$15.6K	–	973
2025 Q4	$15.6K	Buy	+11,002	New	+$16K	﹤0.01%	983

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

StoneX Group's CHRS Position: Q1 2026 in Review

StoneX Group sold out of Coherus Oncology (CHRS) in Q1 2026, closing a stake of 11,002 shares — an estimated $15.6K sold.

StoneX Group first reported a position in CHRS in Q4 2025 and held it in 1 quarter. The position peaked at $15.6K in Q4 2025. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

StoneX Group reported no remaining Coherus Oncology position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 11,002 Coherus Oncology shares in Q1 2026, an estimated $15.6K.
StoneX Group first reported a position in Coherus Oncology in Q4 2025 and held it in 1 quarter.
StoneX Group's Coherus Oncology position peaked at $15.6K in Q4 2025.
158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.